T-cell dysfunctions in myelodysplastic syndromes

2.

Disis

ML

.

Immune regulation of cancer

.

J Clin Oncol

.

2010

;

28

(

29

):

4531

-

4538

.

3.

Waldman

AD

,

Fritz

JM

,

Lenardo

MJ

.

A guide to cancer immunotherapy: from T cell basic science to clinical practice

.

Nat Rev Immunol

.

2020

;

20

(

11

):

651

-

668

.

4.

Balandrán

JC

,

Lasry

A

,

Aifantis

I

.

The role of inflammation in the initiation and progression of myeloid neoplasms

.

Blood Cancer Discov

.

2023

;

4

(

4

):

254

-

266

.

5.

Chokr

N

,

Patel

R

,

Wattamwar

K

,

Chokr

S

.

The rising era of immune checkpoint inhibitors in myelodysplastic syndromes

.

Adv Hematol

.

2018

;

2018

:

2458679

.

6.

Lynch

OF

,

Calvi

LM

.

Immune dysfunction, cytokine disruption, and stromal changes in myelodysplastic syndrome: a review

.

Cells

.

2022

;

11

(

3

):

580

.

7.

Simoni

Y

,

Chapuis

N

.

Diagnosis of myelodysplastic syndromes: from immunological observations to clinical applications

.

Diagnostics (Basel)

.

2022

;

12

(

7

):

1659

.

8.

Symeonidis

A

,

Kourakli

A

,

Katevas

P

, et al.

Immune function parameters at diagnosis in patients with myelodysplastic syndromes: correlation with the FAB classification and prognosis

.

Eur J Haematol

.

1991

;

47

(

4

):

277

-

281

.

9.

Zou

JX

,

Rollison

DE

,

Boulware

D

, et al.

Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome

.

Leukemia

.

2009

;

23

(

7

):

1288

-

1296

.

10.

Xu

L-P

,

Luo

X-H

,

Chang

Y-J

, et al.

High CD4/CD8 ratio in allografts predicts adverse outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation for chronic myeloid leukemia

.

Ann Hematol

.

2009

;

88

(

10

):

1015

-

1024

.

11.

Tay

RE

,

Richardson

EK

,

Toh

HC

.

Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms

.

Cancer Gene Ther

.

2021

;

28

(

1-2

):

5

-

17

.

12.

Jardine

L

,

Barge

D

,

Ames-Draycott

A

, et al.

Rapid detection of dendritic cell and monocyte disorders using CD4 as a lineage marker of the human peripheral blood antigen-presenting cell compartment

.

Front Immunol

.

2013

;

4

:

495

.

13.

Zhu

J

,

Paul

WE

.

CD4 T cells: fates, functions, and faults

.

Blood

.

2008

;

112

(

5

):

1557

-

1569

.

14.

Chatzileontiadou

DSM

,

Sloane

H

,

Nguyen

AT

,

Gras

S

,

Grant

EJ

.

The many faces of CD4(+) T cells: immunological and structural characteristics

.

Int J Mol Sci

.

2020

;

22

(

1

):

73

.

15.

Mosmann

TR

,

Cherwinski

H

,

Bond

MW

,

Giedlin

MA

,

Coffman

RL

.

Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins

.

J Immunol

.

1986

;

136

(

7

):

2348

-

2357

.

16.

Tan

Y

,

Tan

Y

,

Li

J

, et al.

Combined IFN-γ and IL-2 release assay for detect active pulmonary tuberculosis: a prospective multicentre diagnostic study in China

.

J Transl Med

.

2021

;

19

(

1

):

289

.

17.

Li

X

,

Körner

H

,

Liu

X

.

Susceptibility to intracellular infections: contributions of TNF to immune defense

.

Front Microbiol

.

2020

;

11

:

1643

.

18.

Wang

X

,

Wu

DP

,

He

G

,

Miao

M

,

Sun

A

.

Research of subset and function of Th cells in bone marrow of myelodysplastic syndrome patients

.

Blood

.

2005

;

106

(

11

):

4913

.

19.

Liu

Z

,

Xu

X

,

Zheng

L

, et al.

The value of serum IL-4 to predict the survival of MDS patients

.

Eur J Med Res

.

2023

;

28

(

1

):

7

.

20.

van Leeuwen-Kerkhoff

N

,

Westers

TM

,

Poddighe

PJ

,

de Gruijl

TD

,

Kordasti

S

,

van de Loosdrecht

AA

.

Thrombomodulin-expressing monocytes are associated with low-risk features in myelodysplastic syndromes and dampen excessive immune activation

.

Haematologica

.

2020

;

105

(

4

):

961

-

971

.

21.

Hamilton

DH

,

Bretscher

PA

.

Different immune correlates associated with tumor progression and regression: implications for prevention and treatment of cancer

.

Cancer Immunol Immunother

.

2008

;

57

(

8

):

1125

-

1136

.

22.

Hamilton

D

,

Ismail

N

,

Kroeger

D

,

Rudulier

C

,

Bretscher

P

.

Macroimmunology and immunotherapy of cancer

.

Immunotherapy

.

2009

;

1

(

3

):

367

-

383

.

23.

Romagnani

S

,

Maggi

E

,

Liotta

F

,

Cosmi

L

,

Annunziato

F

.

Properties and origin of human Th17 cells

.

Mol Immunol

.

2009

;

47

(

1

):

3

-

7

.

24.

Nistala

K

,

Wedderburn

LR

.

Th17 and regulatory T cells: rebalancing pro- and anti-inflammatory forces in autoimmune arthritis

.

Rheumatology (Oxford)

.

2009

;

48

(

6

):

602

-

606

.

25.

Zhao

J

,

Chen

X

,

Herjan

T

,

Li

X

.

The role of interleukin-17 in tumor development and progression

.

J Exp Med

.

2020

;

217

(

1

):

e20190297

.

26.

Castro

G

,

Liu

X

,

Ngo

K

, et al.

RORγt and RORα signature genes in human Th17 cells

.

PLoS One

.

2017

;

12

(

8

):

e0181868

.

27.

Zhang

Z

,

Li

X

,

Guo

J

, et al.

Interleukin-17 enhances the production of interferon-γ and tumour necrosis factor-α by bone marrow T lymphocytes from patients with lower risk myelodysplastic syndromes

.

Eur J Haematol

.

2013

;

90

(

5

):

375

-

384

.

28.

Kordasti

SY

,

Afzali

B

,

Lim

Z

, et al.

IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome

.

Br J Haematol

.

2009

;

145

(

1

):

64

-

72

.

29.

Hossein-Khannazer

N

,

Zian

Z

,

Bakkach

J

, et al.

Features and roles of T helper 22 cells in immunological diseases and malignancies

.

Scand J Immunol

.

2021

;

93

(

5

):

e13030

.

30.

Jiang

S

,

Dong

C

.

A complex issue on CD4(+) T-cell subsets

.

Immunol Rev

.

2013

;

252

(

1

):

5

-

11

.

31.

Saxton

RA

,

Henneberg

LT

,

Calafiore

M

, et al.

The tissue protective functions of interleukin-22 can be decoupled from pro-inflammatory actions through structure-based design

.

Immunity

.

2021

;

54

(

4

):

660

-

672.e9

.

32.

Yamamoto-Furusho

JK

,

Miranda-Pérez

E

,

Fonseca-Camarillo

G

,

Sánchez-Muñoz

F

,

Dominguez-Lopez

A

,

Barreto-Zuñiga

R

.

Colonic epithelial upregulation of interleukin 22 (IL-22) in patients with ulcerative colitis

.

Inflamm Bowel Dis

.

2010

;

16

(

11

):

1823

.

33.

Shao

LL

,

Zhang

L

,

Hou

Y

, et al.

Th22 cells as well as Th17 cells expand differentially in patients with early-stage and late-stage myelodysplastic syndrome

.

PLoS One

.

2012

;

7

(

12

):

e51339

.

34.

Jogdand

GM

,

Mohanty

S

,

Devadas

S

.

Regulators of Tfh cell differentiation

.

Front Immunol

.

2016

;

7

:

520

.

35.

Qi

H

.

T follicular helper cells in space-time

.

Nat Rev Immunol

.

2016

;

16

(

10

):

612

-

625

.

36.

Kazanietz

MG

,

Durando

M

,

Cooke

M

.

CXCL13 and its receptor CXCR5 in cancer: inflammation, immune response, and beyond

.

Front Endocrinol (Lausanne)

.

2019

;

10

:

471

.

37.

Lampropoulou

P

,

Verigou

E

,

Symeonidis

A

,

Gogos

C

,

Solomou

EE

.

Characterization of T follicular helper cells in patients with low risk myelodysplastic syndromes

.

Blood

.

2013

;

122

(

21

):

4729

.

38.

Lin

YW

,

Slape

C

,

Zhang

Z

,

Aplan

PD

.

NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia

.

Blood

.

2005

;

106

(

1

):

287

-

295

.

39.

Jiang

H

,

Cui

N

,

Yang

L

, et al.

Altered follicular helper T cell impaired antibody production in a murine model of myelodysplastic syndromes

.

Oncotarget

.

2017

;

8

(

58

):

98270

-

98279

.

40.

Xiao

N

,

He

X

,

Niu

H

, et al.

Increased circulating CD4(+)CXCR5(+) cells and IgG4 levels in patients with myelodysplastic syndrome with autoimmune diseases

.

J Immunol Res

.

2021

;

2021

:

4302515

.

41.

Zou

W

.

Regulatory T cells, tumour immunity and immunotherapy

.

Nat Rev Immunol

.

2006

;

6

(

4

):

295

-

307

.

42.

Shevyrev

D

,

Tereshchenko

V

.

Treg heterogeneity, function, and homeostasis

.

Front Immunol

.

2019

;

10

:

3100

.

43.

Wang

C

,

Yang

Y

,

Gao

S

, et al.

Immune dysregulation in myelodysplastic syndrome: clinical features, pathogenesis and therapeutic strategies

.

Crit Rev Oncol Hematol

.

2018

;

122

:

123

-

132

.

44.

Aggarwal

S

,

van de Loosdrecht

AA

,

Alhan

C

,

Ossenkoppele

GJ

,

Westers

TM

,

Bontkes

HJ

.

Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy

.

Br J Haematol

.

2011

;

153

(

5

):

568

-

581

.

45.

Nishikawa

H

,

Koyama

S

.

Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies

.

J Immunother Cancer

.

2021

;

9

(

7

):

e002591

.

46.

Kordasti

SY

,

Ingram

W

,

Hayden

J

, et al.

CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS)

.

Blood

.

2007

;

110

(

3

):

847

-

850

.

47.

Giovazzino

A

,

Leone

S

,

Rubino

V

, et al.

Reduced regulatory T cells (Treg) in bone marrow preferentially associate with the expansion of cytotoxic T lymphocytes in low risk MDS patients

.

Br J Haematol

.

2019

;

185

(

2

):

357

-

360

.

48.

Kotsianidis

I

,

Bouchliou

I

,

Nakou

E

, et al.

Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS)

.

Leukemia

.

2009

;

23

(

3

):

510

-

518

.

49.

Lambert

C

,

Wu

Y

,

Aanei

C

.

Bone marrow immunity and myelodysplasia

.

Front Oncol

.

2016

;

6

:

172

.

50.

Hamdi

W

,

Ogawara

H

,

Handa

H

,

Tsukamoto

N

,

Nojima

Y

,

Murakami

H

.

Clinical significance of regulatory T cells in patients with myelodysplastic syndrome

.

Eur J Haematol

.

2009

;

82

(

3

):

201

-

207

.

51.

Raskov

H

,

Orhan

A

,

Christensen

JP

,

Gögenur

I

.

Cytotoxic CD8+ T cells in cancer and cancer immunotherapy

.

Br J Cancer

.

2021

;

124

(

2

):

359

-

367

.

52.

Szabo

PA

,

Levitin

HM

,

Miron

M

, et al.

Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and disease

.

Nat Commun

.

2019

;

10

(

1

):

4706

.

53.

Philip

M

,

Schietinger

A

.

CD8+ T cell differentiation and dysfunction in cancer

.

Nat Rev Immunol

.

2022

;

22

(

4

):

209

-

223

.

54.

Geerman

S

,

Brasser

G

,

Bhushal

S

, et al.

Memory CD8(+) T cells support the maintenance of hematopoietic stem cells in the bone marrow

.

Haematologica

.

2018

;

103

(

6

):

e230

-

e233

.

55.

Lopes

MR

,

Traina

F

,

Campos

PdM

, et al.

IL10 inversely correlates with the percentage of CD8⁺ cells in MDS patients

.

Leuk Res

.

2013

;

37

(

5

):

541

-

546

.

56.

Zheng

Z

,

Qianqiao

Z

,

Qi

H

,

Feng

X

,

Chunkang

C

,

Xiao

L

.

In vitro deprivation of CD8+ CD57+ T cells promotes the malignant growth of bone marrow colony cells in patients with lower-risk myelodysplastic syndrome

.

Exp Hematol

.

2010

;

38

(

8

):

677

-

684

.

57.

Yang

H

,

Bueso-Ramos

C

,

DiNardo

C

, et al.

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

.

Leukemia

.

2014

;

28

(

6

):

1280

-

1288

.

58.

Sand

K

,

Theorell

J

,

Bruserud

Ø

,

Bryceson

YT

,

Kittang

AO

.

Reduced potency of cytotoxic T lymphocytes from patients with high-risk myelodysplastic syndromes

.

Cancer Immunol Immunother

.

2016

;

65

(

9

):

1135

-

1147

.

59.

Colonna-Romano

G

,

Aquino

A

,

Bulati

M

, et al.

Impairment of gamma/delta T lymphocytes in elderly: implications for immunosenescence

.

Exp Gerontol

.

2004

;

39

(

10

):

1439

-

1446

.

60.

Hayday

AC

.

Gammadelta T cells and the lymphoid stress-surveillance response

.

Immunity

.

2009

;

31

(

2

):

184

-

196

.

61.

Kunzmann

V

,

Wilhelm

M

.

Anti-lymphoma effect of gammadelta T cells

.

Leuk Lymphoma

.

2005

;

46

(

5

):

671

-

680

.

62.

Zhao

Y

,

Niu

C

,

Cui

J

.

Gamma-delta (γδ) T cells: friend or foe in cancer development?

.

J Transl Med

.

2018

;

16

(

1

):

3

.

63.

Mensurado

S

,

Blanco-Domínguez

R

,

Silva-Santos

B

.

The emerging roles of γδ T cells in cancer immunotherapy

.

Nat Rev Clin Oncol

.

2023

;

20

(

3

):

178

-

191

.

64.

Kiladjian

JJ

,

Visentin

G

,

Viey

E

, et al.

Activation of cytotoxic T-cell receptor γδ T lymphocytes in response to specific stimulation in myelodysplastic syndromes

.

Haematologica

.

2008

;

93

(

3

):

381

-

389

.

65.

Barreyro

L

,

Chlon

TM

,

Starczynowski

DT

.

Chronic immune response dysregulation in MDS pathogenesis

.

Blood

.

2018

;

132

(

15

):

1553

-

1560

.

66.

Sallman

DA

,

List

A

.

The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes

.

Blood

.

2019

;

133

(

10

):

1039

-

1048

.

67.

Ganan-Gomez

I

,

Wei

Y

,

Starczynowski

DT

, et al.

Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes

.

Leukemia

.

2015

;

29

(

7

):

1458

-

1469

.

68.

Mayle

A

,

Yang

L

,

Rodriguez

B

, et al.

Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation

.

Blood

.

2015

;

125

(

4

):

629

-

638

.

69.

Li

Z

,

Cai

X

,

Cai

C-L

, et al.

Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies

.

Blood

.

2011

;

118

(

17

):

4509

-

4518

.

70.

Pellicci

DG

,

Uldrich

AP

,

Le Nours

J

, et al.

The molecular bases of δ/αβ T cell-mediated antigen recognition

.

J Exp Med

.

2014

;

211

(

13

):

2599

-

2615

.

71.

Naylor

K

,

Li

G

,

Vallejo

AN

, et al.

The influence of age on T cell generation and TCR diversity

.

J Immunol

.

2005

;

174

(

11

):

7446

-

7452

.

72.

Young

NS

,

Maciejewski

JP

,

Sloand

E

, et al.

The relationship of aplastic anemia and PNH

.

Int J Hematol

.

2002

;

76

(

Suppl 2

):

168

-

172

.

73.

Wechsler

J

,

Bagot

M

,

Nikolova

M

, et al.

Killer cell immunoglobulin-like receptor expression delineates in situ Sézary syndrome lymphocytes

.

J Pathol

.

2003

;

199

(

1

):

77

-

83

.

74.

Kuhn

R

,

Sandu

I

,

Agrafiotis

A

, et al.

Clonally expanded virus-specific CD8 T cells acquire diverse transcriptional phenotypes during acute, chronic, and latent infections

.

Front Immunol

.

2022

;

13

:

782441

.

75.

Kochenderfer

JN

,

Kobayashi

S

,

Wieder

ED

,

Su

C

,

Molldrem

JJ

.

Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression

.

Blood

.

2002

;

100

(

10

):

3639

-

3645

.

76.

Epperson

DE

,

Nakamura

R

,

Saunthararajah

Y

,

Melenhorst

J

,

Barrett

AJ

.

Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process

.

Leuk Res

.

2001

;

25

(

12

):

1075

-

1083

.

77.

Sloand

EM

,

Mainwaring

L

,

Fuhrer

M

, et al.

Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome

.

Blood

.

2005

;

106

(

3

):

841

-

851

.

78.

Wlodarski

MW

,

Gondek

LP

,

Nearman

ZP

, et al.

Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome

.

Blood

.

2006

;

108

(

8

):

2632

-

2641

.

79.

Fozza

C

,

Contini

S

,

Galleu

A

, et al.

Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset

.

Exp Hematol

.

2009

;

37

(

8

):

947

-

955

.

80.

Fozza

C

,

Corda

G

,

Barraqueddu

F

, et al.

Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia

.

Leuk Res

.

2015

;

39

(

9

):

957

-

963

.

81.

Abbas

HA

,

Reville

PK

,

Jiang

X

, et al.

Response to hypomethylating agents in myelodysplastic syndrome is associated with emergence of novel TCR clonotypes

.

Front Immunol

.

2021

;

12

:

659625

.

82.

Hanahan

D

.

Hallmarks of cancer: new dimensions

.

Cancer Discov

.

2022

;

12

(

1

):

31

-

46

.

83.

Fane

M

,

Weeraratna

AT

.

How the ageing microenvironment influences tumour progression

.

Nat Rev Cancer

.

2020

;

20

(

2

):

89

-

106

.

84.

Seidel

JA

,

Otsuka

A

,

Kabashima

K

.

Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations

.

Front Oncol

.

2018

;

8

:

86

.

85.

Meng

F

,

Li

L

,

Lu

F

, et al.

Overexpression of TIGIT in NK and T cells contributes to tumor immune escape in myelodysplastic syndromes

.

Front Oncol

.

2020

;

10

:

1595

.

86.

Haroun

F

,

Solola

SA

,

Nassereddine

S

,

Tabbara

I

.

PD-1 signaling and inhibition in AML and MDS

.

Ann Hematol

.

2017

;

96

(

9

):

1441

-

1448

.

87.

Coats

T

,

Smith

Ae

,

Mourikis

TP

,

Irish

JM

,

Kordasti

S

,

Mufti

GJ

.

Mass cytometry reveals PD1 upregulation is an early step in MDS disease progression

.

Blood

.

2016

;

128

(

22

):

4296

.

88.

Tcvetkov

NY

,

Morozova

EV

,

Epifanovskaya

OS

, et al.

Profile of checkpoint molecules expression on bone marrow cell populations in patients with high-risk myelodysplastic syndrome

.

Blood

.

2020

;

136

(

suppl 1

):

43

-

44

.

89.

Kitagawa

M

,

Saito

I

,

Kuwata

T

, et al.

Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes

.

Leukemia

.

1997

;

11

(

12

):

2049

-

2054

.

90.

Stifter

G

,

Heiss

S

,

Gastl

G

,

Tzankov

A

,

Stauder

R

.

Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis

.

Eur J Haematol

.

2005

;

75

(

6

):

485

-

491

.

91.

Basiorka

AA

,

McGraw

KL

,

Eksioglu

EA

, et al.

The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype

.

Blood

.

2016

;

128

(

25

):

2960

-

2975

.

92.

Thompson

CB

,

Allison

JP

.

The emerging role of CTLA-4 as an immune attenuator

.

Immunity

.

1997

;

7

(

4

):

445

-

450

.

93.

Aref

S

,

El Agdar

M

,

El Sebaie

A

,

Abouzeid

T

,

Sabry

M

,

Ibrahim

L

.

Prognostic value of CD200 expression and soluble CTLA-4 concentrations in intermediate and high-risk myelodysplastic syndrome patients

.

Asian Pac J Cancer Prev

.

2020

;

21

(

8

):

2225

-

2230

.

94.

Tao

J

,

Li

L

,

Wang

Y

,

Fu

R

,

Wang

H

,

Shao

Z

.

Increased TIM3+CD8+T cells in myelodysplastic syndrome patients displayed less perforin and granzyme B secretion and higher CD95 expression

.

Leuk Res

.

2016

;

51

:

49

-

55

.

95.

Fu

R

,

Li

L

,

Hu

J

, et al.

Elevated TIM3 expression of T helper cells affects immune system in patients with myelodysplastic syndrome

.

J Investig Med

.

2019

;

67

(

8

):

1125

-

1130

.

96.

Tcvetkov

N

,

Gusak

A

,

Morozova

E

, et al.

Immune checkpoints bone marrow expression as the predictor of clinical outcome in myelodysplastic syndrome

.

Leuk Res Rep

.

2020

;

14

:

100215

.

97.

Zeidan

AM

,

Giagounidis

A

,

Sekeres

MA

, et al.

STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2

.

Future Oncol

.

2023

;

19

(

9

):

631

-

642

.

98.

Garcia-Manero

G

,

Chien

KS

,

Montalban-Bravo

G

.

Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management

.

Am J Hematol

.

2020

;

95

(

11

):

1399

-

1420

.

99.

Rodriguez-Sevilla

JJ

,

Adema

V

,

Garcia-Manero

G

,

Colla

S

.

Emerging treatments for myelodysplastic syndromes: biological rationales and clinical translation

.

Cell Rep Med

.

2023

;

4

(

2

):

100940

.

100.

Garcia-Manero

G

,

Ribrag

V

,

Zhang

Y

,

Farooqui

M

,

Marinello

P

,

Smith

BD

.

Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study

.

Leuk Lymphoma

.

2022

;

63

(

7

):

1660

-

1668

.

101.

Chien

KS

,

Kim

K

,

Nogueras-Gonzalez

GM

, et al.

Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome

.

Br J Haematol

.

2021

;

195

(

3

):

378

-

387

.

102.

Garcia-Manero

G

,

Sasaki

K

,

Montalban-Bravo

G

, et al.

A phase II study of nivolumab or ipilimumab with or without azacitidine for patients with myelodysplastic syndrome (MDS)

.

Blood

.

2018

;

132

(

suppl 1

):

465-465

.

103.

Morita

K

,

Kantarjian

HM

,

Montalban Bravo

G

, et al.

A phase II study of double immune checkpoint inhibitor blockade with nivolumab and ipilimumab with or without azacitidine in patients with myelodysplastic syndrome (MDS)

.

Blood

.

2020

;

136

(

suppl 1

):

7

-

9

.

104.

Brunner

AM

,

Esteve

J

,

Porkka

K

, et al.

Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (Pts) with very high/high-risk myelodysplastic syndrome (vHR/HR-MDS) and acute myeloid leukemia (AML): final analysis from a phase Ib study

.

Blood

.

2021

;

138

(

suppl 1

):

244

.

105.

Zeidan

AM

,

Ando

K

,

Rauzy

O

, et al.

Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial

.

Lancet Haematol

.

2024

;

11

(

1

):

e38

-

e50

.

106.

Sallman

DA

,

Kerre

T

,

Havelange

V

, et al.

CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial

.

Lancet Haematol

.

2023

;

10

(

3

):

e191

-

e202

.

107.

Sallman

DA

,

Elmariah

H

,

Sweet

K

, et al.

Phase 1/1b safety study of Prgn-3006 Ultracar-T in patients with relapsed or refractory CD33-positive acute myeloid leukemia and higher risk myelodysplastic syndromes

.

Blood

.

2022

;

140

(

suppl 1

):

10313

-

10315

.

108.

Vey

N

,

Davidson-Moncada

J

,

Uy

GL

, et al.

Interim results from a phase 1 first-in-human study of flotetuzumab, a CD123 × CD3 bispecific DART molecule, in AML/MDS

.

Ann Oncol

.

2017

;

28

(

suppl 5

):

v355

.

109.

Vey

N

,

Davidson-Moncada

J

,

Uy

GL

, et al.

Interim results from a Phase 1 First-in-Human Study of Flotetuzumab, a CD123 × CD3 Bispecific DART® Molecule, in AML/MDS

.

ESMO

.

2017

.

110.

Uckun

FM

,

Watts

J

,

Mims

AS

, et al.

A clinical phase 1B study of the CD3xCD123 bispecific antibody APVO436 in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome

.

Cancers (Basel)

.

2021

;

13

(

21

):

5287

.

111.

Nguyen

D

,

Ravandi

F

,

Wang

SA

, et al.

A phase II study of vibecotamab, a CD3-CD123 bispecific T-cell engaging antibody, for MDS or CMML after hypomethylating failure and in MRD-positive AML

.

Blood

.

2023

;

142

(

suppl 1

):

322

.

112.

Nair-Gupta

P

,

Diem

M

,

Reeves

D

, et al.

A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia

.

Blood Adv

.

2020

;

4

(

5

):

906

-

919

.

113.

Garcia-Manero

G

,

Jacoby

M

,

Sallman

DA

,

Han

T

,

Guenot

J

,

Feldman

E

.

A phase I study of AMV564 in patients with intermediate or high-risk myelodysplastic syndromes

.

J Clin Oncol

.

2019

;

37

(

suppl 15

):

TPS7071

.

114.

Neelapu

SS

,

Locke

FL

,

Bartlett

NL

, et al.

Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma

.

N Engl J Med

.

2017

;

377

(

26

):

2531

-

2544

.

115.

Schuster

SJ

,

Bishop

MR

,

Tam

CS

, et al.

Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma

.

N Engl J Med

.

2019

;

380

(

1

):

45

-

56

.

116.

Abramson

JS

,

Palomba

ML

,

Gordon

LI

, et al.

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

.

Lancet

.

2020

;

396

(

10254

):

839

-

852

.

117.

Chua

CC

,

Cheok

KPL

.

Taking a step forward in CAR T-cell therapy for acute myeloid leukaemia and myelodysplastic syndrome

.

Lancet Haematol

.

2023

;

10

(

3

):

e161

-

e162

.

118.

Stevens

BM

,

Zhang

W

,

Pollyea

DA

, et al.

CD123 CAR T cells for the treatment of myelodysplastic syndrome

.

Exp Hematol

.

2019

;

74

:

52

-

63.e3

.

119.

Kenderian

SS

,

Ruella

M

,

Shestova

O

, et al.

CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia

.

Leukemia

.

2015

;

29

(

8

):

1637

-

1647

.

120.

Liu

H

,

Wang

S

,

Xin

J

,

Wang

J

,

Yao

C

,

Zhang

Z

.

Role of NKG2D and its ligands in cancer immunotherapy

.

Am J Cancer Res

.

2019

;

9

(

10

):

2064

-

2078

.

121.

Diermayr

S

,

Himmelreich

H

,

Durovic

B

, et al.

NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities

.

Blood

.

2008

;

111

(

3

):

1428

-

1436

.

122.

Driouk

L

,

Gicobi

J

,

Kamihara

Y

, et al.

Chimeric antigen receptor T cells targeting NKG2D-ligands show robust efficacy against acute myeloid leukemia and T-cell acute lymphoblastic leukemia

.

Blood

.

2019

;

134

(

suppl 1

):

1930

-

1931

.

123.

Heine

R

,

Thielen

FW

,

Koopmanschap

M

, et al.

Health economic aspects of chimeric antigen receptor T-cell therapies for hematological cancers: present and future

.

Hemasphere

.

2021

;

5

(

2

):

e524

.

124.

Depil

S

,

Duchateau

P

,

Grupp

SA

,

Mufti

G

,

Poirot

L

.

'Off-the-shelf' allogeneic CAR T cells: development and challenges

.

Nat Rev Drug Discov

.

2020

;

19

(

3

):

185

-

199

.

125.

Buccheri

S

,

Guggino

G

,

Caccamo

N

,

Li Donni

P

,

Dieli

F

.

Efficacy and safety of γδT cell-based tumor immunotherapy: a meta-analysis

.

J Biol Regul Homeost Agents

.

2014

;

28

(

1

):

81

-

90

.

126.

Haber

L

,

Olson

K

,

Kelly

MP

, et al.

Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning

.

Sci Rep

.

2021

;

11

(

1

):

14397

.

127.

Allen

C

,

Zeidan

AM

,

Bewersdorf

JP

.

BiTEs, DARTS, BiKEs and TriKEs-are antibody based therapies changing the future treatment of AML?

.

Life (Basel)

.

2021

;

11

(

6

):

465

.

128.

Teramura

M

,

Kimura

A

,

Iwase

S

, et al.

Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan

.

Blood

.

2007

;

110

(

6

):

1756

-

1761

.

129.

Tsuda

K

,

Yamanaka

K

,

Kitagawa

H

, et al.

Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation of naïve T cells into cytokine-producing mature T cells

.

PLoS One

.

2012

;

7

(

2

):

e31465

.

130.

Mohty

M

.

Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond

.

Leukemia

.

2007

;

21

(

7

):

1387

-

1394

.

131.

NCCN Guidelines Version Myelodysplastic Syndromes (1.2023).

National Comprehensive Cancer Network

;

2023

.

132.

Haider

M

,

Al Ali

N

,

Padron

E

, et al.

Immunosuppressive therapy: exploring an underutilized treatment option for myelodysplastic syndrome

.

Clin Lymphoma Myeloma Leuk

.

2016

(

16 suppl

):

S44

-

S48

.

133.

Stahl

M

,

Bewersdorf

JP

,

Giri

S

,

Wang

R

,

Zeidan

AM

.

Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis

.

Haematologica

.

2020

;

105

(

1

):

102

-

111

.